This week, male crabs stalk their prey’s movements, a new dry eye drug faces off with Allergan’s Restasis in a phase 2 trial and neckties restrict blood flow to the brain. Source: AAO
In this observational cross-sectional analysis, investigators evaluated the association between macula vascular density assessed by OCT angiography (OCT-A) and central visual field (VF) results. Source: AAO
This study describes the effect of heat and ice on ptosis in patients with myasthenia gravis (MG). Source: AAO
This study retrospectively evaluated the melanoma-specific mortality among patients who underwent a biopsy for posterior uveal melanoma. Source: AAO
This multicenter, open-label, prospective analysis evaluated the long-term safety and efficacy of the Kamra small-aperture intracorneal inlay. Source: AAO
Oyster Point Pharma reported positive preliminary results from a phase 2b trial testing their novel drug for dry eye disease. Source: AAO
This retrospective review assessed the risk of severe vision loss after orbital surgery. Source: AAO
This week, a drop-sized lawsuit is squeezed out of deliberations by the U.S. Supreme Court, an orange a day may keep macular degeneration away and Japan’s Takeda is one step closer to buying Shire for $62 billion. Source: AAO
This open-label multicenter study evaluated the human monoclonal antibody, cemiplimab, for treatment of advanced cutaneous squamous-cell carcinoma. Cemiplimab is a high-affinity monoclonal antibody directed against programmed death 1 (PD-1). Source: AAO
Alleye, a mobile medical application developed to monitor progression of patients with AMD, was approved by the FDA earlier this week. Source: AAO